Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bone

Showing results (161-170 of 192) with videos related to

Pageof 20
Sort By:
The Journal of Clinical Endocrinology and Metabolism|January 1, 1997
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study CentersH G Bone, R W Downs, J R Tucci, et al.
The New England Journal of Medicine|March 19, 2004
Ten years' experience with alendronate for osteoporosis in postmenopausal womenHenry G Bone, David Hosking, Jean-Pierre Devogelaer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 26, 2018
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group StudyMichael R McClung, Jacques P Brown, Adolfo Diez-Perez, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 7, 2009
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone massD L Kendler, L Bessette, C D Hill, et al.
Calcified Tissue International|April 2, 2008
Sequestosome 1 (SQSTM1) mutations in Paget's disease of bone from the United StatesEmily C Rhodes, Teresa L Johnson-Pais, Frederick R Singer, et al.
Obstetrics and Gynecology|July 2, 2013
Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trialChris Recknor, Edward Czerwinski, Henry G Bone, et al.
The Journal of Clinical Endocrinology and Metabolism|June 9, 2016
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesP D Miller, N Pannacciulli, J P Brown, et al.
The Journal of Clinical Endocrinology and Metabolism|May 26, 2018
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal OsteoporosisHenry G Bone, Felicia Cosman, Paul D Miller, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 30, 2014
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture TrialH G Bone, D W Dempster, J A Eisman, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 12, 2015
Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture TrialH G Bone, D W Dempster, J A Eisman, et al.
Pageof 20

Showing results (161-170 of 192) with videos related to

Sort By:
Pageof 20
The Journal of Clinical Endocrinology and Metabolism|January 1, 1997
Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study CentersH G Bone, R W Downs, J R Tucci, et al.
The New England Journal of Medicine|March 19, 2004
Ten years' experience with alendronate for osteoporosis in postmenopausal womenHenry G Bone, David Hosking, Jean-Pierre Devogelaer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 26, 2018
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group StudyMichael R McClung, Jacques P Brown, Adolfo Diez-Perez, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 7, 2009
Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone massD L Kendler, L Bessette, C D Hill, et al.
Calcified Tissue International|April 2, 2008
Sequestosome 1 (SQSTM1) mutations in Paget's disease of bone from the United StatesEmily C Rhodes, Teresa L Johnson-Pais, Frederick R Singer, et al.
Obstetrics and Gynecology|July 2, 2013
Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trialChris Recknor, Edward Czerwinski, Henry G Bone, et al.
The Journal of Clinical Endocrinology and Metabolism|June 9, 2016
Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral BisphosphonatesP D Miller, N Pannacciulli, J P Brown, et al.
The Journal of Clinical Endocrinology and Metabolism|May 26, 2018
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal OsteoporosisHenry G Bone, Felicia Cosman, Paul D Miller, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|November 30, 2014
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture TrialH G Bone, D W Dempster, J A Eisman, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 12, 2015
Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture TrialH G Bone, D W Dempster, J A Eisman, et al.
Pageof 20